{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:20:04Z","timestamp":1707524404985},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,9]]},"DOI":"10.7759\/cureus.20295","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T12:50:20Z","timestamp":1639054220000},"source":"Crossref","is-referenced-by-count":0,"title":["Bortezomib-Induced Reversible Cardiomyopathy: Recovered with Guideline-Directed Medical Therapy"],"prefix":"10.7759","author":[{"given":"Swethika  H","family":"Sundaravel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalyn I","family":"Marar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhannad A","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhamed","family":"Baljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy  R","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle RA","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al.. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003, 78:21-33. 10.4065\/78.1.21","journal-title":"Mayo Clin Proc"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809057562","article-title":"Multiple myeloma in young patients: clinical presentation and treatment approach","volume":"30","author":"Blad\u00e9 J","year":"1998","unstructured":"Blad\u00e9 J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma. 1998, 30:493-501. 10.3109\/10428199809057562","journal-title":"Leuk Lymphoma"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan AJ","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, et al.. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018, 4:1221-7. 10.1001\/jamaoncol.2018.2128","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.2916.2916","article-title":"Cardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practice","volume":"120","author":"Kistler KD","year":"2012","unstructured":"Kistler KD, Rajangam K, Faich G, Lanes S. Cardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practice. Blood. 2012, 120:2916-2916. 10.1182\/blood.V120.21.2916.2916","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-018-0618-y","article-title":"Cardiovascular complications of multiple myeloma treatment: evaluation, management, and prevention","volume":"20","author":"Lee DH","year":"2018","unstructured":"Lee DH, Fradley MG. Cardiovascular complications of multiple myeloma treatment: evaluation, management, and prevention. Curr Treat Options Cardiovasc Med. 2018, 20:19. 10.1007\/s11936-018-0618-y","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0784-4","article-title":"Cardiovascular complications associated with multiple myeloma therapies: incidence, pathophysiology, and management","volume":"21","author":"Patel VG","year":"2019","unstructured":"Patel VG, Cornell RF. Cardiovascular complications associated with multiple myeloma therapies: incidence, pathophysiology, and management. Curr Oncol Rep. 2019, 21:29. 10.1007\/s11912-019-0784-4","journal-title":"Curr Oncol Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018351","article-title":"Cardiovascular complications of novel multiple myeloma treatments","volume":"133","author":"Li W","year":"2016","unstructured":"Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, Moslehi J. Cardiovascular complications of novel multiple myeloma treatments. Circulation. 2016, 133:908-12. 10.1161\/CIRCULATIONAHA.115.018351","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020265","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"12","author":"Ito S","year":"2020","unstructured":"Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel). 2020, 12:10.3390\/cancers12020265","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00924","article-title":"Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations","volume":"17","author":"Stone JR","year":"2021","unstructured":"Stone JR, Kanneganti R, Abbasi M, Akhtari M. Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations. JCO Oncol Pract. 2021, 17:228-36. 10.1200\/OP.20.00924","journal-title":"JCO Oncol Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087671","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao Y","year":"2014","unstructured":"Xiao Y, Yin J, Wei J, Shang Z. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS One. 2014, 9:e87671. 10.1371\/journal.pone.0087671","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson PG","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, et al.. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003, 348:2609-17. 10.1056\/NEJMoa030288","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-00931-w","article-title":"Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management","volume":"22","author":"Wu P","year":"2020","unstructured":"Wu P, Oren O, Gertz MA, Yang EH. Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management. Curr Oncol Rep. 2020, 22:66. 10.1007\/s11912-020-00931-w","journal-title":"Curr Oncol Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.5748","article-title":"Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway","volume":"33","author":"Mitsiades CS","year":"2015","unstructured":"Mitsiades CS. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway. J Clin Oncol. 2015, 33:782-5. 10.1200\/JCO.2014.55.5748","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin EW","year":"2015","unstructured":"Grandin EW, Ky B, Cornell RF, Carver J, Lenihan DJ. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail. 2015, 21:138-44. 10.1016\/j.cardfail.2014.11.008","journal-title":"J Card Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3568","article-title":"Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis","volume":"10","author":"Bishnoi R","year":"2021","unstructured":"Bishnoi R, Xie Z, Shah C, Bian J, Murthy HS, Wingard JR, Farhadfar N. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis. Cancer Med. 2021, 10:70-8. 10.1002\/cam4.3568","journal-title":"Cancer Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40292-018-0256-1","article-title":"Evaluation of cardiovascular toxicity associated with treatments containing proteasome inhibitors in multiple myeloma therapy","volume":"25","author":"Iannaccone A","year":"2018","unstructured":"Iannaccone A, Bruno G, Ravera A, et al.. Evaluation of cardiovascular toxicity associated with treatments containing proteasome inhibitors in multiple myeloma therapy. High Blood Press Cardiovasc Prev. 2018, 25:209-18. 10.1007\/s40292-018-0256-1","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson PG","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, et al.. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005, 352:2487-98. 10.1056\/NEJMoa043445","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.172126","article-title":"Cardiotoxicity associated with bortezomib: A single-center experience","volume":"13","author":"Gurram MK","year":"2017","unstructured":"Gurram MK, Pulivarthi S, Ehresmann K, Mathew J. Cardiotoxicity associated with bortezomib: A single-center experience. J Cancer Res Ther. 2017, 13:961-3. 10.4103\/0973-1482.172126","journal-title":"J Cancer Res Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.08.004","article-title":"Bortezomib-based chemotherapy for multiple myeloma patients without comorbid cardiovascular disease shows no cardiotoxicity","volume":"18","author":"Heitner SB","year":"2018","unstructured":"Heitner SB, Minnier J, Naher A, et al.. Bortezomib-based chemotherapy for multiple myeloma patients without comorbid cardiovascular disease shows no cardiotoxicity. Clin Lymphoma Myeloma Leuk. 2018, 18:796-802. 10.1016\/j.clml.2018.08.004","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos MA","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016, 17:27-38. 10.1016\/S1470-2045(15)00464-7","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3402\/jchimp.v5.28982","article-title":"Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy","volume":"5","author":"Meseeha MG","year":"2015","unstructured":"Meseeha MG, Kolade VO, Attia MN. Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy. J Community Hosp Intern Med Perspect. 2015, 5:28982. 10.3402\/jchimp.v5.28982","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4021\/cr105e","article-title":"Bortezomib-induced severe congestive heart failure","volume":"1","author":"Jerkins JH","year":"2010","unstructured":"Jerkins JH, Suciu A, Mazimba S, Calvo A. Bortezomib-induced severe congestive heart failure. Cardiol Res. 2010, 1:20-3. 10.4021\/cr105e","journal-title":"Cardiol Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000340050","article-title":"Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature","volume":"128","author":"Bockorny M","year":"2012","unstructured":"Bockorny M, Chakravarty S, Schulman P, Bockorny B, Bona R. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta Haematol. 2012, 128:244-7. 10.1159\/000340050","journal-title":"Acta Haematol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-129","article-title":"Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report","volume":"6","author":"Voortman J","year":"2006","unstructured":"Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer. 2006, 6:129. 10.1186\/1471-2407-6-129","journal-title":"BMC Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-011-9146-7","article-title":"Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma","volume":"12","author":"Gupta A","year":"2012","unstructured":"Gupta A, Pandey A, Sethi S. Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma. Cardiovasc Toxicol. 2012, 12:184-7. 10.1007\/s12012-011-9146-7","journal-title":"Cardiovasc Toxicol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06659.x","article-title":"Unexpected cardiotoxicity in haematological bortezomib treated patients","volume":"138","author":"Enrico O","year":"2007","unstructured":"Enrico O, Gabriele B, Nadia C, et al.. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol. 2007, 138:396-7. 10.1111\/j.1365-2141.2007.06659.x","journal-title":"Br J Haematol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3456287","article-title":"Bortezomib-induced complete heart block and myocardial scar: The potential role of cardiac biomarkers in monitoring cardiotoxicity","volume":"2016","author":"Diwadkar S","year":"2016","unstructured":"Diwadkar S, Patel AA, Fradley MG. Bortezomib-induced complete heart block and myocardial scar: The potential role of cardiac biomarkers in monitoring cardiotoxicity. Case Rep Cardiol. 2016, 2016:3456287. 10.1155\/2016\/3456287","journal-title":"Case Rep Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210367839","article-title":"Complete heart block secondary to bortezomib use in multiple myeloma","volume":"17","author":"Dasanu CA","year":"2011","unstructured":"Dasanu CA. Complete heart block secondary to bortezomib use in multiple myeloma. J Oncol Pharm Pract. 2011, 17:282-4. 10.1177\/1078155210367839","journal-title":"J Oncol Pharm Pract"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2011.52.1.196","article-title":"Complete atrioventricular block secondary to bortezomib use in multiple myeloma","volume":"52","author":"Lee WS","year":"2011","unstructured":"Lee WS, Kim DH, Shin SH, et al.. Complete atrioventricular block secondary to bortezomib use in multiple myeloma. Yonsei Med J. 2011, 52:196-8. 10.3349\/ymj.2011.52.1.196","journal-title":"Yonsei Med J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies","volume":"10","author":"Buza V","year":"2017","unstructured":"Buza V, Rajagopalan B, Curtis AB. Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies. Circ Arrhythm Electrophysiol. 2017, 10:10.1161\/CIRCEP.117.005443","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.090690","article-title":"Cardiotoxicity of the anticancer therapeutic agent bortezomib","volume":"176","author":"Nowis D","year":"2010","unstructured":"Nowis D, Maczewski M, Mackiewicz U, et al.. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol. 2010, 176:2658-68. 10.2353\/ajpath.2010.090690","journal-title":"Am J Pathol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"Maddox TM","year":"2021","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, et al.. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021, 77:772-810. 10.1016\/j.jacc.2020.11.022","journal-title":"J Am Coll Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060030-00011","article-title":"Metoprolol: a review of its use in chronic heart failure","volume":"60","author":"Prakash A","year":"2000","unstructured":"Prakash A, Markham A. Metoprolol: a review of its use in chronic heart failure. Drugs. 2000, 60:647-78. 10.2165\/00003495-200060030-00011","journal-title":"Drugs"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000035653.72855.bf","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer M","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, et al.. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002, 106:2194-9. 10.1161\/01.cir.0000035653.72855.bf","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf S","year":"1991","unstructured":"Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991, 325:293-302. 10.1056\/NEJM199108013250501","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn JN","year":"2001","unstructured":"Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001, 345:1667-75. 10.1056\/NEJMoa010713","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt B","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999, 341:709-17. 10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-00310-6","article-title":"Ketone bodies for the starving heart","volume":"2","author":"Schulze PC","year":"2020","unstructured":"Schulze PC, Wu JM. Ketone bodies for the starving heart. Nat Metab. 2020, 2:1183-5. 10.1038\/s42255-020-00310-6","journal-title":"Nat Metab"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: \u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano JL","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al.. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: \u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016, 37:2768-801. 10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano G","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, et al.. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020, 31:171-90. 10.1016\/j.annonc.2019.10.023","journal-title":"Ann Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0b013e32832f3ff2","article-title":"Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance","volume":"11","author":"Foley PW","year":"2010","unstructured":"Foley PW, Hamilton MS, Leyva F. Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance. J Cardiovasc Med (Hagerstown). 2010, 11:386-8. 10.2459\/JCM.0b013e32832f3ff2","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale D","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, et al.. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015, 131:1981-8. 10.1161\/CIRCULATIONAHA.114.013777","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/74099-bortezomib-induced-reversible-cardiomyopathy-recovered-with-guideline-directed-medical-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:13Z","timestamp":1707507193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/74099-bortezomib-induced-reversible-cardiomyopathy-recovered-with-guideline-directed-medical-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.20295","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,9]]}}}